Literature DB >> 15225876

ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers.

Cameron N Johnstone1, Sergi Castellví-Bel, Laura M Chang, Xavier Bessa, Hiroshi Nakagawa, Hideki Harada, Raphael K Sung, Josep M Piqué, Antoni Castells, Anil K Rustgi.   

Abstract

The RHO family of small GTPases has multiple functions, including regulation of cytoskeletal organization, cell cycle progression and cell migration, among others. The key members of this family are RHO, RAC and CDC42. Active GTP-bound RHO proteins are down-regulated by RHO GTPase-activating proteins (RHOGAPs). Herein, we describe the identification, characterization and mutational analysis of a novel RHOGAP designated as ARHGAP8, which is located within a critical region of loss-of-heterozygosity on chromosome 22q13.31 in breast and colorectal carcinomas. ARHGAP8 shares an identical genomic organization with ARHGAP1/CDC42GAP/p50RHOGAP and the corresponding proteins share the same functional domains that distinguish them from other ARHGAP members. These domains include the C-terminal RHOGAP domain, a central SH3-binding motif, and an N-terminal BNIP-2/CDC42GAP homology (BCH)/Sec14p-like domain. Three alternatively spliced ARHGAP8 transcripts were expressed in normal mammary gland and colon, which differed in the size of the BCH/Sec14p-like domain only. PCR-SSCP analyses revealed a total of six germline missense variants in individuals with colorectal or breast cancer; however, somatic mutations were not identified. Surprisingly, ARHGAP8 expression was up-regulated in the majority of primary colorectal tumors analyzed. Taken together, ARHGAP8 encodes a novel RHOGAP with unique functional domains that is highly homologous to ARHGAP1/CDC42GAP/p50RHOGAP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15225876     DOI: 10.1016/j.gene.2004.01.025

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  23 in total

1.  Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor gamma 1 phosphorylation.

Authors:  Cameron N Johnstone; Perry S Mongroo; A Sophie Rich; Michael Schupp; Mark J Bowser; Andrew S Delemos; John W Tobias; Yingqiu Liu; Gregory E Hannigan; Anil K Rustgi
Journal:  Mol Cell Biol       Date:  2007-11-12       Impact factor: 4.272

Review 2.  Rho GTPases: functions and association with cancer.

Authors:  Saskia I J Ellenbroek; John G Collard
Journal:  Clin Exp Metastasis       Date:  2007-11-14       Impact factor: 5.150

3.  BPGAP1 spatially integrates JNK/ERK signaling crosstalk in oncogenesis.

Authors:  T Jiang; C Q Pan; B C Low
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

Review 4.  Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?

Authors:  P R McHenry; T Vargo-Gogola
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

5.  Mammalian diseases of phosphatidylinositol transfer proteins and their homologs.

Authors:  Aaron H Nile; Vytas A Bankaitis; Aby Grabon
Journal:  Clin Lipidol       Date:  2010-12-01

6.  Inhibitory effects of Arhgap6 on cervical carcinoma cells.

Authors:  Junping Li; Yang Liu; Yihua Yin
Journal:  Tumour Biol       Date:  2015-12-01

7.  IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2.

Authors:  Perry S Mongroo; Felicite K Noubissi; Miriam Cuatrecasas; Jiri Kalabis; Catrina E King; Cameron N Johnstone; Mark J Bowser; Antoni Castells; Vladimir S Spiegelman; Anil K Rustgi
Journal:  Cancer Res       Date:  2011-01-20       Impact factor: 12.701

Review 8.  Fixing the GAP: The role of RhoGAPs in cancer.

Authors:  Gabriel Kreider-Letterman; Nicole M Carr; Rafael Garcia-Mata
Journal:  Eur J Cell Biol       Date:  2022-02-10       Impact factor: 6.020

9.  The BNIP-2 and Cdc42GAP homology (BCH) domain of p50RhoGAP/Cdc42GAP sequesters RhoA from inactivation by the adjacent GTPase-activating protein domain.

Authors:  Yi Ting Zhou; Li Li Chew; Sheng-cai Lin; Boon Chuan Low
Journal:  Mol Biol Cell       Date:  2010-07-21       Impact factor: 4.138

10.  Targets of miR-200c mediate suppression of cell motility and anoikis resistance.

Authors:  Erin N Howe; Dawn R Cochrane; Jennifer K Richer
Journal:  Breast Cancer Res       Date:  2011-04-18       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.